Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry
スポンサーリンク
概要
- 論文の詳細を見る
- 2001-08-25
著者
-
Baud-camus F.
Department De Pharmacie Clinique Upres 2706 Faculte De Pharmacie
-
Marquet P.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
-
Marquet P.
Service De Pharmacologie Et Toxicologie Hopital Universitaire Dupuytren
-
SOURSAC M.
Department de Pharmacie Clinique, UPRES 2706, Faculte de Pharmacie
-
DAVRINCHE C.
Department de Pharmacie Clinique, UPRES 2706, Faculte de Pharmacie
-
FARINOTTI R.
Department de Pharmacie Clinique, UPRES 2706, Faculte de Pharmacie
-
Soursac M.
Department De Pharmacie Clinique Upres 2706 Faculte De Pharmacie
-
Farinotti R
Department De Pharmacie Clinique Upres 2706 Faculte De Pharmacie
-
Farinotti R.
Department De Pharmacie Clinique Faculte De Pharmacie
-
Davrinche C.
Department De Pharmacie Clinique Faculte De Pharmacie
-
Davrinche C.
Department De Pharmacie Clinique Upres 2706 Faculte De Pharmacie
関連論文
- Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization
- Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry
- High-performance liquid chromatographic assay for 3'-amino-3'deoxythymidine in plasma, with 9-fluorenyl methyl chloroformate as the derivatization agent